Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Endpoints winners and losers 2024: Best and worst biotech trends
Dec 19, 2024 · Endpoints News reviews 2024's biopharma winners & losers: Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.
Endpoints News – Biotech and pharma business news, with a focus …
All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs. SIGN UP NOW
Clinical Trials Day 2024
Dec 17, 2024 · Join Endpoints for a series of conversations on the latest trends in clinical trials in the US and abroad, the regulatory environment, and how expectations from the industry and beyond are shifting the trial strategies of the future.
Special report 2024: Meet 20 women breaking new ground in …
Oct 7, 2024 · Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020. Natalie passed away earlier ...
Endpoints at #ASCO24
Jun 4, 2024 · Each year, the oncology world looks to the ASCO meeting to make sense of the clinical cancer landscape. Data coming out of the meeting will signal pipeline strengths and weaknesses, and point to the next directions for cancer treatment. We’ll cover the biggest news out of the meeting and hear how oncology leaders see the field moving in the next year.</p>
News – Endpoints News
reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email
Big dreams dominate among next-gen biotech players
Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or go down fighting for a landmark change.
Commure’s latest acquisition sends follow-up texts to patients
Dec 20, 2024 · General Catalyst-backed Commure acquires Memora Health, a startup that automates patient follow-up texts. Commure continues building healthcare platform.
Endpoints at #JPM24 | Primed to unlock biopharma's next …
Join Endpoints on Monday as we sit down with leading minds in research, investing and deal making. Our Monday sessions will feature some of pharma’s top M&A execs, a view from the top at one of biotech’s creation engines, a candid look at the capital raising process at two up-and-coming companies and inside perspectives from the activist and M&A world.